[email protected]
CDI - Contrive Datum Insights
Medical Devices

Radiation Oncology Market Size, Growth Rate and Regional Outlook to 2034: Drivers, Risks and Segment Shares

An analysis of radiation oncology market size, the 7.48% growth rate to 2034, what drives and could slow it, and where regional and segment revenue sits.

Published: Industry: Medical DevicesRead time: ~5 min

Radiation oncology revenue stood at USD 9.8 billion in 2025 and is forecast to reach USD 18.7 billion by 2034. The forecast rests on a 7.48% annual rate, and the shape of that rate matters more than the headline. This analysis draws on CDI's radiation oncology market report and looks at where the growth comes from, how it could miss and which regions and treatment modalities hold the revenue.

Market size and growth rate

The base year is 2025 and the forecast runs from 2026 to 2034. Revenue was USD 7.3 billion in 2020 and USD 9.3 billion in 2024, before reaching USD 9.8 billion in 2025. The historical period from 2020 to 2024 compounded at 6.07%.

The forecast period then runs at 7.48%, ending 2034 at USD 18.7 billion. That is a faster rate than the market has recorded, but it is a modest step up from an observed trend and not a proposed reversal. The forecast applies no ramp. The 7.48% runs evenly across every year, so there is no late-period surge carrying the total.

The distinction is useful for planning. A forecast that extends a trend asks a reader to believe the past continues. A forecast that proposes a turn asks a reader to believe something has changed. This one is closer to the first kind.

What is driving it

Three observations in the data explain the rate.

The first is Carbon Ion Therapy, which adds the most incremental growth. It compounds at 13.58% against 7.48% for the market as a whole. Its revenue rises from USD 0.147 billion in 2025 to USD 0.468 billion in 2034, and its share of revenue moves from 1.5% to 2.5%. At the other end of the treatment modality axis, growth is 5.31%. That spread decides whether the market's 7.48% holds. A portfolio weighted away from the fast line tracks below the market even when the market grows in every segment.

The second is geography. Growth lands where the revenue already is. North America is the largest region at USD 4.018 billion in 2025, or 41% of global revenue, and reaches USD 6.732 billion by 2034. Europe holds 26% of revenue, at USD 2.548 billion in 2025 and USD 4.395 billion in 2034. Most of the base and most of the growth sit in those two regions. A plan spread evenly across regions will over-invest outside them.

The third is the historical record. The base has grown every year since 2020, which supports the view that demand for treatment capacity is steady and not cyclical. Readers comparing this against other equipment categories can look at the telemedicine equipment market, forecast at a CAGR of 11.5%, and the physiotherapy equipment market, at 5.93%. Radiation oncology at 7.48% sits between the two.

What could slow it

The report models a bear case. It names three causes: delayed capital budgets and proton financing, slower radioligand scale-up because of isotope supply limits, and reimbursement cuts that lower revenue per course. On that path the market reaches USD 16.1 billion by 2034 instead of USD 18.7 billion. The starting point is unchanged at USD 9.8 billion in 2025.

Two structural features sharpen the risk.

External Beam Radiation Therapy holds the blended rate down. It accounts for 72% of 2025 revenue, or USD 7.056 billion, and it grows at only 5.7% against the market's 7.48%. Revenue still reaches USD 11.594 billion by 2034, and its share falls to 62%. This is a drag on the average and not a decline. It does mean the market's forecast is, to a large extent, a forecast for one treatment modality. If the largest line underperforms its 5.7%, there is little elsewhere on the axis to compensate quickly, because the faster lines start from small bases.

Concentration also appears in the leading region. North America is worth USD 4.018 billion in 2025, and USD 3.6 billion of that is the United States, which is 89.6% of the region. The region reaches USD 6 billion in 2034 on the United States alone. Regional totals therefore move largely with one country's demand. A regional forecast is more exposed to single-country conditions than its size suggests.

There is an upside case as well. Faster uptake of adaptive and radioligand therapy, earlier financing of proton projects and reimbursement that supports shorter courses without cutting per-course payment would lift 2034 revenue to USD 20.9 billion. The bear case of USD 16.1 billion and the bull case of USD 20.9 billion bracket the base forecast of USD 18.7 billion, and each reader should test them against their own view of capital budgets and reimbursement.

Where the growth sits

Regional shares of 2025 revenue are as follows:

  • North America: 41%
  • Europe: 26%
  • Asia Pacific: 24%
  • Latin America: 4.5%
  • Middle East and Africa: 4.5%

North America leads with 41% of global revenue and still holds 36% in 2034. Asia Pacific is close to Europe in share, and the report covers all five regions in full.

On the treatment modality axis, 2025 revenue divides as follows:

  • External Beam Radiation Therapy: 72%
  • Systemic Radioisotope Therapy: 10%
  • Proton Therapy: 8.5%
  • Brachytherapy: 6%
  • Intraoperative Radiotherapy: 2%
  • Carbon Ion Therapy: 1.5%

Share moves toward Carbon Ion Therapy over the forecast, from 1.5% to 2.5%. Taking a position there does not require displacing whoever holds External Beam Radiation Therapy, which is the harder and more expensive contest. For a supplier, the choice is between defending a large, slower line and building exposure to a small, faster one.

The report also segments the market by technique, product and service offering, cancer type, treatment intent, fractionation regimen, end user, patient age group and procurement model. Cancer type is the cut most relevant to demand. The remote patient monitoring market carries cancer as one of its own application segments, which is a useful companion for readers following oncology care beyond the treatment room.

For the full segmentation and regional breakdown, see the radiation oncology market report.